In summary, Th17 cells via IL-17 drive inflammation, immune evasion, EMT, metastasis, and angiogenesis in NSCLC, highlighting their crucial role in tumor progression and as a potential therapeutic target. This evidence concerns the gene IL17A and non-small cell lung carcinoma.